 Home > Active Ingredient News > Antitumor Therapy > BMC Cancer: Unresectable stage III non-small cell lung cancer (NSCLC) with platinum-based chemotherapy followed by platinum-based chemotherapy can prolong survival

BMC Cancer: Unresectable stage III non-small cell lung cancer (NSCLC) with platinum-based chemotherapy followed by platinum-based chemotherapy can prolong survival

 Last Update: 2022-04-24
 Source: Internet
 Author: User

Tags

pancreatic cancer cells

a hair

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Platinum-based chemoradiation is the standard of care for unresectable stage III non-small cell lung cancer ( NSCLC ) .
However, few studies have evaluated the efficacy of subsequent chemotherapy for relapsed NSCLC after platinum-based chemoradiotherapy .
Therefore, a team from Japan conducted a related study to evaluate the efficacy of platinum-based chemotherapy as second-line therapy in patients with unresectable stage III NSCLC after progression on platinum-based chemoradiotherapy .
The results were published in the journal BMC Cancer .

Platinum-based chemoradiation is the standard of care for unresectable stage III non-small cell lung cancer ( NSCLC ) .

However, few studies have evaluated the efficacy of subsequent chemotherapy for relapsed NSCLC after platinum-based chemoradiotherapy .
Therefore, a team from Japan conducted a related study to evaluate the efficacy of platinum-based chemotherapy as second-line therapy in patients with unresectable stage III NSCLC after progression on platinum-based chemoradiotherapy .
The results were published in the journal BMC Cancer .

We retrospectively enrolled patients with unresectable stage III NSCLC who progressed after receiving platinum-based chemoradiotherapy and divided the patients into platinum -based chemotherapy (platinum) group and single-agent chemotherapy (non-platinum) group according to the type of second-line chemotherapy .

The therapeutic effects of the two groups were evaluated .

Of the 320 patients included, 119 (37%) received platinum -based doublet chemotherapy (platinum group) and 201 (63%) single-agent chemotherapy (non-platinum group)
.

The mean age was 64 years, 87% of patients were male, and 94% were current or former smokers

Of the 320 patients included, 119 (37%) received platinum -based doublet chemotherapy (platinum group) and 201 (63%) single-agent chemotherapy (non-platinum group)

In the entire cohort, median OS from second-line chemotherapy was 12.

5 months (95% CI, 10.
8-14.

In the entire cohort, median OS from second-line chemotherapy was 12.

The median time interval between initiation of first-line CRT and initiation of second-line chemotherapy was 8.
6 months
.

Using the 8.

The median time interval between initiation of first-line CRT and initiation of second-line chemotherapy was 8.

Univariate analysis identified second-line platinum-based chemotherapy, female sex, and clinical stage IIIA as significant predictors of better OS
.

Multivariate analysis showed that second-line platinum-based chemotherapy (HR: 0.

Univariate analysis identified second-line platinum-based chemotherapy, female sex, and clinical stage IIIA as significant predictors of better OS

For second-line therapy, the ORR was 26.
1% and 7.
0% in the platinum and non-platinum groups, respectively (p<0.
001)
.
There was no significant difference in OS between platinum and non-platinum groups starting with third-line therapy (median OS: 12.
7 vs.
8.
7 months, HR: 0.
78, 95% CI: 0.
52 1.
17, p=0.
24)
.

In patients with an interval of ≥3 months between first-line CRT and second-line chemotherapy, the OS of the platinum group was significantly better than that of the non-platinum group (median OS: 20.
5 vs.
10.
5 months, HR: 0.
57, 95% CI: 0.
40 0.
80, p= 0.
001)
.
The 12-month OS rate was 70.
5% in the platinum group and 38.
7% in the non-platinum group
.
According to RECIST, the ORR of second-line chemotherapy was significantly higher in the platinum group than in the non-platinum group (23.
9% vs.
7.
3%; p< 0.
001)
.

Taken together, these studies suggest that platinum-based combined chemotherapy as second-line therapy may prolong the survival of patients with unresectable stage III NSCLC after progression on platinum-based chemoradiotherapy
.
Therefore, recombination of platinum-based chemotherapy in such patients may be a promising treatment
.
Studies have shown that platinum-based chemotherapy as second-line therapy may prolong the survival of patients with unresectable stage III NSCLC after progression on platinum-based chemoradiotherapy
.
Therefore, recombination of platinum-based chemotherapy in such patients may be a promising treatment
.
Studies have shown that platinum-based chemotherapy as second-line therapy may prolong the survival of patients with unresectable stage III NSCLC after progression on platinum-based chemoradiotherapy
.
Therefore, recombination of platinum-based chemotherapy in such patients may be a promising treatment
.

Original source:

Miyawaki E, Kenmotsu H, Shintani Y, Sekine I, Shukuya T, Takayama K, Inoue A, Okamoto I, Kiura K, Takahashi K, Yamamoto N, Kawaguchi T, Miyaoka E, Yoshino I, Date H.
Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study.
BMC Cancer.
2022 Mar 29;22(1):342.
doi: 10.
1186/s12885-022-09441-3.
PMID: 35351059; PMCID : PMC8962203.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.